Immunotherapy plus radiation before liver cancer surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one liver tumor that can be removed with surgery, and it's less than 12 cm (about 5 inches) across.
- You have not had any prior treatment for liver cancer (like surgery, radiation, or other therapies).
- Your liver is working well (Child-Pugh Class A) and your overall health is good (ECOG score 0 or 1).
- You do not have active autoimmune diseases, active hepatitis B or C, HIV, or other serious infections.
- You are able to have surgery and are willing to receive two immunotherapy drugs (durvalumab and tremelimumab) along with radiation before surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests combining an immunotherapy drug (sintilimab) with focused radiation (SBRT) before surgery for liver cancer that has spread into a branch of the portal vein. The goal is to see if this combination can shrink the tumor and make surgery more successful.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This Phase 2 trial studies durvalumab and tremelimumab (immunotherapy medicines) in people with resectable early or intermediate-stage liver cancer (HCC). It aims to see how well these medicines work before/around the time of surgery, and whether they can improve outcomes.
This trial tests whether combining the immunotherapy drug sintilimab with targeted radiation therapy before surgery can improve outcomes for patients with liver cancer that can be surgically removed. It aims to shrink the tumor and reduce the chance of recurrence.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.